NEWS ALERTS
NEWS ALERTS

OUR BUSINESS

CONCEPT & PIPELINE

SAVES LIVES AND HEALTH CARE COSTS

$38,469
Avg. 1-year cost of CRC treatment 9

Ongoing testing every 3 years

Pathway to Success

$38,469
Avg. 1-year cost of CRC treatment 9

Ongoing testing every 3 years

Pathway to Success

U.S. Preventive Services Task Force recommends screening starting at age 45, and testing every 3 years (for average risk individuals) when using a combined stool DNA/fecal immunochemical test. 10

Making CRC prevention a standard test every 3 years after age 45 is advised to detect early-stage anomalies.10

Regular CRC testing means fewer unnecessary colonoscopies and higher user acceptance, directly leading to increased screening participation. 10

Annual testing costs per patient are minimal (especially when compared to late-stage treatments of CRC).

  • Enormous savings in first level treatment costs  (one case of metastasized CRC represents substantial treatment costs).

  • Reduced second level treatment costs.

9 Annual cost for late-stage treatment – National Center for Biotechnology Information.
10 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening

Commercial Pipeline Development: Future Products

In addition to our flagship ColoAlert product, Mainz Biomed is also developing:

Developing a novel early detection pancreatic cancer screening test

  • As GenX individuals age into their 40’s and 50’s they become part of the age group recommended to begin testing for CRC and more.
  • Mainz BioMed is currently developing proprietary genetic testing methods for pancreatic cancer.
  • Fighting what could soon become the world’s second most deadly cancer.*
  • Convenient stool test for at-home use.
  • Potential for over 50 million tests per year in Europe alone
  • Supported by federal grant from Germany’s Federal Ministry for Education and Research.
  • Cost of goods sold (COGS) & reimbursement analogous to ColoAlert program.

*https://www.pancan.org/press-releases/pancreatic-cancer-still-on-path-to-become-second-leading-cause-of-cancer-related-death-in-u-s-by-2020/

* Artist rendering. Product under development.

GenoStick Technology

  • High patient acceptance due to convenient sampling.
  • Prototypical application already developed for an Abacavir hypersensitivity test.
  • Up to 4 genetic biomarkers for broad application.
  • Applicable for various genetic diagnostics.
  • Supported by federal grant from Germany’s Federal Ministry for Education and Research.

SITE MENU

News Alerts Signup

If you would like to be kept up to date with the very latest news, please enter your details in the form and we will keep you updated.